Developing Innovative Ligands for Nuclear Receptors to Eradicate Cancer Relapse
The aim of the Marie Sklodowska-Curie Doctoral Network “eRaDicate” is to develop new therapies against cancer stem cell-driven relapse and metastasis. The 11 doctoral candidates (DCs) of eRaDicate will be trained not only to perform original and independent research on an internationally competitive level, but will also be endowed with a creative, critical and entrepreneurial mindset, coupled with persistence in following their objectives.
News
Secondment Sucess: Giorgia Risso in Birmingham
Another eRaDicate secondment has been successfully completed. Our Marie Skłodowska-Curie Doctoral Researcher Giorgia Risso…
Postcards from Spetses: Alice and Giorgia at the EMBO|FEBS Summer School
Our PhD researchers Giorgia Risso and Alice Keirle took part in the EMBO | FEBS Lecture Course “Cancer…
Next Stop: Australia – Carmen Receives ÖFG Travel Grant
Carmen has been awarded a EUR 1,500 travel grant from the Austrian Science Fund (ÖFG) under the International Communication…
Achievements
Publications
Awards
Presentations
Metabolic Interactions of Side-chain Extended and Unsaturated Vitamin D Analogs with Cytochrome P450 Enzymes – Zołek et al.
The active form of vitamin D3 (1,25D3) has anticancer potential, but its clinical use is limited by calcemic side effects and rapid breakdown by…
Next Stop: Australia – Carmen Receives ÖFG Travel Grant
Carmen has been awarded a EUR 1,500 travel grant from the Austrian Science Fund (ÖFG) under the International Communication…
From Training to Podium: Carmen’s Contributions to ECDP 2026
At the 22nd European Congress on Digital Pathology (ECDP 2026) in Graz, Carmen delivered an oral presentation in the Bias in AI…
Consortium
The eRaDicate consortium consists of eight academic and one industrial and beneficiaries, as well as twelve associated partners to provide training and secondments.
Beneficiaries
Associated Partners
